Results 211 to 220 of about 3,169,653 (411)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer's Disease. [PDF]

Pharmaceuticals (Basel)
Steinfield SR, Stenn DF, Chen H, Kalisch BE.   +3 more
europepmc   +1 more source

Efficacy of the neurokinin‐1 receptor antagonist aprepitant in children with cyclical vomiting syndrome

Alimentary Pharmacology and Therapeutics, 2014
F. Cristofori, N. Thapar, E. Saliakellis, N. Kumaraguru, M. Elawad, F. Kiparissi, J. Köglmeier, P. Andrews, K. Lindley, O. Borrelli   +9 more
semanticscholar   +1 more source

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis. [PDF]

Ren Fail
Cheungpasitporn W, Krisanapan P, Suppadungsuk S, Thongprayoon C, Fülöp T, Miao J, Soliman KM, Ho YS.   +7 more
europepmc   +1 more source

Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys

, 1986
Marilyn J. Koering, David Healy, Gary D. Hodgen   +2 more
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Deficiency of interleukin-1 receptor antagonist: A systematic review. [PDF]

Arch Rheumatol
Gonçalves Barros WR, Gonçalves Júnior J.   +1 more
europepmc   +1 more source

1,3,8‐ and 1,3,7‐substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction [PDF]

, 1989
Ana M. Sebastião, Joaquim A. Ribeiro
openalex   +1 more source

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

FEBS Letters, 1994
M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, Christian Congy, Serge Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J. Breliere, G. Le Fur   +13 more
semanticscholar   +1 more source